Syncona takes part in oversubscribed funding round for OMass
28th Apr 2022 08:59
(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.
Read moreSyncona's Anaveon to present first clinical data from ANV419 study
11th Apr 2022 07:49
(Sharecast News) - Healthcare company Syncona said on Monday that its portfolio company, Anaveon AG, a clinical-stage immuno-oncology business, had announced that the first clinical data from the ongoing Phase I/II study of its lead programme, ANV419, would be presented in a poster at the American Association for Cancer Research's annual meeting in New Orleans.
Read moreSyncona's Q3 a 'period of significant activity'
10th Feb 2022 07:47
(Sharecast News) - Life sciences firm Syncona said on Thursday that the third quarter had been a "period of significant activity", with $674.0m raised by its portfolio and its third successful exit to date.
Read moreSyncona sells Gyroscope to Novartis for up to $1.5bn
22nd Dec 2021 07:03
(Sharecast News) - Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.
Read moreSyncona net asset value slips in first half
11th Nov 2021 09:42
(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down from £1.3bn or 193.8p per share at the end of March.
Read moreSyncona's Freeline makes progress in dose-finding trials
10th Nov 2021 08:13
(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' dose-finding clinical trial of 'FLT190' for the treatment of Fabry disease on Wednesday, with the second patient dosed generating "encouraging" data.
Read moreSyncona reports positive asset value return in final results
17th Jun 2021 07:46
(Sharecast News) - Healthcare investment company Syncona reported year-end net assets of £1.3bn in its final results on Thursday, up from £1.25bn in the prior year.
Read moreSyncona's Gyroscope Therapeutics postpones IPO
7th May 2021 07:31
(Sharecast News) - Syncona portfolio company Gyroscope Therapeutics Holdings has postponed plans for its initial public offering in light of current market conditions, the healthcare firm said on Friday.
Read moreAchilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake
31st Mar 2021 07:41
(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).
Read moreSyncona invests £31m in Gyroscope
26th Mar 2021 07:59
(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.
Read moreSyncona makes decent progress in December quarter
11th Feb 2021 07:56
(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.
Read moreSyncona upbeat on Autolus US public offering pricing
10th Feb 2021 09:31
(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).
Read moreSyncona investment Achilles upbeat on safety review of trials
5th Feb 2021 08:01
(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.
Read moreSyncona upbeat on developments at Autolus
6th Jan 2021 08:36
(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.
Read moreSyncona reports improved performance for past six months as clinical trials resume
19th Nov 2020 08:16
(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.
Read more